AmylinIAPP

Co-secreted with insulin; the satiety and gastric-emptying partner.

EndogenousEstablished

Identity

Class: Islet amyloid polypeptide (37 aa)
Source: Pancreatic islet beta cells (with insulin)
Receptor: Amylin receptors (calcitonin receptor + RAMP complexes)

Key properties

Molecular weight

~3,903.3 Da

Half-life (native)

~13 min (native)

Model dosing

Approximate values for the native hormone. Engineered analogs are often deliberately larger and far longer-acting.

Mechanism

Amylin is released alongside insulin and complements it: it slows gastric emptying, suppresses inappropriate glucagon secretion, and promotes satiety. Together with insulin it shapes the post-meal glucose excursion.

Reference notes

Amylin and insulin are co-packaged and co-secreted — a built-in partnership.
Amylin-pathway agonism is studied as an adjunct to incretin therapy for added satiety.
Native human amylin aggregates readily, which shaped the design of stabilized analogs.

Selected literature

Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.

1.Amylin: Pharmacology, Physiology, and Clinical Potential · Pharmacological reviews, 2015 · PMID 26071095
2.Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus · Nature reviews. Endocrinology, 2025 · PMID 40360789